Rheumatoid Arthritis Pharmaceutical Market in China 2021
- 市场报告
- ID: HL10105C
- 交货时间: 1 工作日
- 标签: Rheumatoid Arthritis Pharmaceutical
描述
The rheumatoid arthritis pharmaceutical market in China in terms of revenue is set to grow by US$ 7 亿期间 2021-2027, 以复合年增长率增长 (复合年增长率) 的 21.8% 在预测期内, 据数据和分析公司 StrategyHelix 称.
该报告提供了该时期的最新市场规模数据 2017-2020 并预测到 2027 covering key market aspects like sales value for rheumatoid arthritis pharmaceutical. The China rheumatoid arthritis pharmaceutical market is segmented on the basis of type. 按类型, it is categorized into conventional synthetic disease-modifying antirheumatic drugs (DMARDs), non-steroidal anti-inflammatory pharmaceuticals, 和别的.
The report has profiled some of the key players of the market such as AbbVie Inc., 约翰逊 & Johnson International Inc., Pfizer Inc., Roche Holding AG, Sunshine Guojian Pharmaceutical (上海) 钴. 有限公司, Zhejiang Hisun Pharmaceutical Co. 有限公司.
该报告对于活跃在该行业的公司和组织来说是宝贵的资源. It provides a cohesive picture of the rheumatoid arthritis pharmaceutical market to help drive informed decision making for industry executives, 政策制定者, 学术的, 和分析师.
报告范围
类型: conventional synthetic disease-modifying antirheumatic drugs (DMARDs), non-steroidal anti-inflammatory pharmaceuticals, 和别的
考虑年数: 本报告涵盖期间 2017 到 2027
利益相关者的主要好处
Get a comprehensive picture of the China rheumatoid arthritis pharmaceutical market
精准定位增长领域和投资趋势
Understand what the future of the rheumatoid arthritis pharmaceutical market in China looks like
确定竞争格局和机会之窗
目录
1. 市场定义
2. 研究方法论
3. 市场数据 & 外表
3.1 市场价值
3.2 市场价值预测
4. Rheumatoid Arthritis Pharmaceutical Market by Type
4.1 Conventional Synthetic Disease-Modifying Antirheumatic Drugs (Dmards)
4.2 Non-Steroidal Anti-Inflammatory Pharmaceuticals
4.3 其他的
5. 公司简介
5.1 艾伯维公司.
5.2 约翰逊 & Johnson International, 公司.
5.3 Pfizer, 公司.
5.4 Roche Holding AG
5.5 Sunshine Guojian Pharmaceutical (上海) 公司。, 有限公司.
5.6 Zhejiang Hisun Pharmaceutical Co., 有限公司.
6. 附录
6.1 关于StrategyHelix
6.2 免责声明